Camille Bouget. Image: Scienta Lab
Camille Bouget discusses how artificial intelligence is impacting innovation in the treatment of diseases affecting the immune system.
“Immuno-inflammatory diseases are often described as niche. They are not,” Camille Bouget, the CEO and co-founder of healthcare start-up Scienta Lab, explained to SiliconRepublic.com.
With as many as one out of every 10 people in Western countries potentially impacted by an immuno-inflammatory condition, she noted, symptoms are often debilitating and the available therapeutic options frequently deeply inadequate for a significant proportion of patients.
This is why, in 2021, Bouget co-founded Scienta Lab, a biotechnology company that aims to advance research within immunology via modern technologies such as artificial intelligence and EVA, the organisation’s multimodal AI model purpose-built for translational research in immunology and inflammation.
